Myxoinflammatory Fibroblastic Sarcoma: Review and Update
1From the Department of Pathology, University of Michigan/Michigan Medicine, Ann Arbor, Michigan.
Archives of Pathology & Laboratory Medicine
|October 27, 2017
Summary
Myxoinflammatory fibroblastic sarcoma is a rare soft tissue tumor often misdiagnosed due to its benign appearance. This review highlights its features to improve diagnosis and treatment of this aggressive cancer.
Area of Science:
- Oncology
- Pathology
- Dermatology
Background:
- Myxoinflammatory fibroblastic sarcoma (MFS) is a rare soft tissue tumor.
- It predominantly affects adult patients in the distal extremities.
- MFS exhibits a high rate of local recurrence and a low rate of metastasis.
Purpose of the Study:
- To review the clinicopathologic features of MFS.
- To detail the microscopic spectrum, including aggressive variants.
- To discuss molecular features and its relation to hemosiderotic fibrolipomatous tumor.
Main Methods:
- Literature review and case experience synthesis.
- Analysis of clinicopathologic and molecular data.
- Comparative study with hemosiderotic fibrolipomatous tumor.
Main Results:
- MFS can present with benign-appearing clinical features.
- Microscopic features are often underrecognized, leading to misdiagnosis.
- High-grade aggressive variants exist within the MFS spectrum.
Conclusions:
- Accurate diagnosis of MFS requires recognition of its broad clinicopathologic spectrum.
- Improved understanding of MFS features can prevent inadequate treatment and misdiagnosis.
- Further research into MFS molecular features and its relationship with hemosiderotic fibrolipomatous tumor is warranted.
